Allegens Company Limited Pharmaceutical Import Profile — Vietnam (DGFT 2022–2026)

Name: Allegens Company Limited Pharmaceutical Import Records from India — 2 Products, $800.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Allegens Company Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $800.0K Trade | TransData Nexus

Allegens Company Limited

Pharmaceutical Importer · Vietnam · Analgesics & Antipyretics Focus · $800.0K Total Trade · DGFT Verified

Allegens Company Limited is a pharmaceutical importer based in Vietnam with a total trade value of $800.0K across 2 products in 2 therapeutic categories. Based on 16 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Allegens Company Limited sources from 31 verified Indian suppliers, with Unosource Pharma Limited accounting for 16.7% of imports.

Allegens Company Limited — Import Portfolio & Supplier Network

Allegens Company Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Allegens Company Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Unosource Pharma Limited	$1.7M	139	16.7%
Cadila Pharmaceuticals Limited	$1.4M	38	13.7%
Indchemie Health Specialities Private Limited	$758.8K	68

What Formulations Does Allegens Company Limited Import?

Formulation	Value	Ships
Pha drg & med rabicad 20 TAB. cont. rabeprazole sodium qty.	$369.7K	9
Sucralfate 1000MG (sucrafil suspension)	$181.7K	4
Pha drg & med rabicad 20 cont. rabeprazole sodium qty.	$175.5K	4
Pha drg & med rabicad 20 TAB. cont.	$150.0K	3
Pharmaceutical product medicine:moxcor	$148.0K	10
Zanobapine (visa no vn-16470-13) batch	$122.5K	3
Atoronobi-20 (visa no. vn-16656-13)	$118.0K	3
Moov 7.5 (meloxicam tablets BP 7.5 MG)	$114.8K	3
Lediceti (visa no. vn-16997-13) batch	$112.7K	3
Pharmaceuticals products - ( finished product) orle 20 MG capsule 10x10 ( omeprazole capsules 20MG )	$103.6K	3
Amoxicillin&potassium clavulanate 625 MG	$100.0K	2
Pharmaceutical products medicine	$100.0K	2
Rabicad 20 (r/m : rabeprazole sodium)	$100.0K	2
Dipsope 5MG 100tabs vnm (dnnk allegens)	$98.5K	4
Troypofol propofol injection i.v (1% w/v)1x20ml b/no.t269560 m/d.18-12-23 e/d.17-12-25 b/no.t269561 m/d.19-12-23	$90.6K	3

Allegens Company Limited imports 430 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Meloxicam	Analgesics & Antipyretics	$400.0K	8	0.2%	9
2	Moov	Brand Names & OTC Products	$400.0K	8	3.0%	5

Allegens Company Limited imports 2 pharmaceutical products across 2 categories into Vietnam totaling $800.0K.

Allegens Company Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Allegens Company Limited, established on May 21, 2009, is a foreign-invested enterprise headquartered at No. 1-3, Street No. 45, Ward 6, District 4, Ho Chi Minh City, Vietnam. The company operates as a limited liability entity specializing in management consultancy services, with a registered capital of VND 4,063,000,000. Allegens is a group company of Albios and Y-med, aiming to make quality healthcare more accessible in the ASEAN region. Over the years, Allegens has diversified its operations to include sales, marketing, distribution, trading, and project consultation of pharmaceutical and healthcare products. The company has expanded its presence beyond Vietnam, establishing offices in India, Myanmar, and Cambodia, thereby positioning itself as a comprehensive one-stop solution for pharmaceutical and healthcare needs across the region.

2Distribution Network

Allegens Company Limited's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across Vietnam and neighboring ASEAN countries. The company adheres to Good Distribution Practice (GDP) norms for the storage and distribution of products, ensuring that the entire supply chain is monitored for end-to-end results. With a dedicated logistics team, Allegens ensures timely delivery of order quantities to end customers, including hospitals, clinics, doctors, and end-users. The company's extensive distribution network in major countries in Asia enables it to deliver healthcare products on time across Vietnam, Myanmar, and other Asian countries.

3Industry Role

Allegens Company Limited plays a multifaceted role in Vietnam's pharmaceutical supply chain. As an importer, the company sources a diverse range of pharmaceutical products from international markets, including India, Europe, and other parts of the world. Beyond importing, Allegens is actively involved in sales, marketing, distribution, trading, and project consultation, positioning itself as a comprehensive player in the pharmaceutical sector. The company's diverse portfolio of over 200 pharmaceutical products underscores its significant presence in the market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Allegens Company Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Allegens Company Limited's sourcing strategy reveals a notable concentration in its supplier base. The company has engaged with 31 unique Indian suppliers, with the top five suppliers accounting for a substantial portion of its imports. For instance, Unosource Pharma Limited and Cadila Pharmaceuticals Limited each contributed approximately 16.7% and 13.7% of the total import value, respectively. This concentration indicates a strategic choice to establish strong partnerships with key suppliers, potentially ensuring favorable terms and consistent product quality. However, such dependency also introduces risks related to supply chain disruptions or changes in supplier dynamics. The shipment data, with 16 total shipments, suggests a stable relationship with these suppliers, but the limited number of shipments may also indicate a need for diversification to mitigate potential risks.

2Supply Chain Resilience

Allegens Company Limited's supply chain resilience is influenced by its sourcing patterns and supplier relationships. The company's reliance on a select group of Indian suppliers, while beneficial for establishing strong partnerships, may pose challenges in terms of supply chain flexibility. The limited number of shipments (16) could indicate a need for diversification to enhance resilience. Additionally, the company's adherence to GDP norms for storage and distribution, along with a dedicated logistics team, contributes positively to the overall supply chain robustness.

Importing Pharmaceuticals into Vietnam — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Vietnam

1Regulatory Authority & Framework

In Vietnam, the pharmaceutical industry is regulated by the Ministry of Health, which oversees the import, distribution, and sale of pharmaceutical products. The primary legislation governing pharmaceutical imports is the Law on Pharmacy No. 105/2016/QH13, issued on April 6, 2016. This law outlines the conditions for importing pharmaceutical products, including requirements for import licenses and registration with the Drug Administration of Vietnam (DAV). Decree No. 54/2017/ND-CP, issued on May 8, 2017, provides detailed provisions for implementing the Law on Pharmacy, specifying the conditions for obtaining import licenses and the registration process for pharmaceutical products. (hmlf.vn)

2Import Licensing & GMP

Importing pharmaceutical products into Vietnam requires compliance with specific licensing and certification requirements. Entities must possess an import license issued by the Ministry of Health to import pharmaceuticals. Additionally, imported drugs must be registered with the Drug Administration of Vietnam (DAV) and granted Market Authorization (MA) before distribution. The registration process involves submitting a dossier that includes detailed information about the drug and its safety. (hmlf.vn) Regarding Good Manufacturing Practice (GMP) certifications, Vietnam recognizes various international standards, including EU GMP, WHO GMP, and PIC/S. Importers are required to ensure that their suppliers hold valid GMP certifications from recognized authorities to guarantee product quality and safety.

Allegens Company Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Allegens Company Limited's product strategy focuses on importing pharmaceutical products that address prevalent health concerns in Vietnam. The company's portfolio includes analgesics and antipyretics, as well as brand-name and over-the-counter (OTC) products, indicating a strategic focus on widely used medications. The market demand for these products is driven by the high incidence of pain-related conditions and the growing preference for accessible OTC medications among consumers. By focusing on these therapeutic areas, Allegens aims to meet the healthcare needs of the Vietnamese population effectively.

2Sourcing Profile

Allegens Company Limited's sourcing strategy emphasizes the importation of generic pharmaceutical products, particularly in the analgesics and antipyretics categories. The company's preference for finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, aligns with its goal to provide ready-to-use medications to the Vietnamese market. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a suitable sourcing partner for Allegens. This sourcing approach enables Allegens to offer cost-effective and high-quality pharmaceutical products to meet the demands of the Vietnamese healthcare sector.

3Market Positioning

Seller's Guide — How to Become a Supplier to Allegens Company Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Allegens Company Limited. The company's focus on importing generic pharmaceutical products, particularly in the analgesics and antipyretics categories, presents avenues for suppliers to introduce complementary products or expand existing offerings. Gaps in Allegens' current sourcing may include specific formulations or dosage forms not currently represented in its portfolio. Indian exporters can explore these opportunities by aligning their product offerings with Allegens' strategic focus and the unmet needs in the Vietnamese market.

2Requirements & Qualifications

Indian exporters seeking to supply Allegens Company Limited and the Vietnamese market must ensure that

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Allegens Company Limited

What products does Allegens Company Limited import from India?

Allegens Company Limited imports 2 pharmaceutical products across 2 categories. Top imports: Meloxicam ($400.0K), Moov ($400.0K).

Who supplies pharmaceuticals to Allegens Company Limited from India?

Allegens Company Limited sources from 31 verified Indian suppliers. The primary supplier is Unosource Pharma Limited (16.7% of imports, $1.7M).

What is Allegens Company Limited's total pharmaceutical import value?

Allegens Company Limited's total pharmaceutical import value from India is $800.0K, based on 16 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Allegens Company Limited focus on?

Allegens Company Limited imports across 2 categories. The largest: Analgesics & Antipyretics (50.0%), Brand Names & OTC Products (50.0%).

Get Full Allegens Company Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.